Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 3/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493603 | 0.87 | KMT2A (0.44) | TSHRGSK3BKDM4EMAPTKMT2A | |
| SCHEMBL30497244 | 0.81 | FABP4 (0.50) | FABP4GCGRGIPR | |
| SCHEMBL25295021 | 0.81 | FABP4 (0.50) | FABP4GCGRGIPR | |
| SCHEMBL493217 | 0.81 | GCGR (0.49) | GSK3BGCGR | |
| SCHEMBL493923 | 0.78 | KMT2A (0.65) | KDM4EMAPTKMT2A | |
| SCHEMBL494418 | 0.77 | TPMT (0.48) | TSHRNPC1RAB9A | |
| SCHEMBL493533 | 0.76 | NPC1 (0.51) | TSHRMAPTKMT2ANPC1RAB9A | |
| SCHEMBL19380053 | 0.73 | MAOB (0.56) | TSHRKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL493896 | 0.72 | FAAH (0.56) | TSHRKDM4EMAPTKMT2ANPC1 | |
| SCHEMBL493260 | 0.72 | SMN1; SMN2 (0.75) | MAPTKMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | FABP4 300/4885TSHR 4051/4885GSK3B 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.